Crinetics Pharmaceuticals CRNX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's investing cash flow?
- Crinetics Pharmaceuticals (CRNX) reported investing cash flow of -$252.36M in Q1 2026.
- How has Crinetics Pharmaceuticals's investing cash flow changed year-over-year?
- Crinetics Pharmaceuticals's investing cash flow decreased by 193.6% year-over-year, from -$85.96M to -$252.36M.
- What is the long-term trend for Crinetics Pharmaceuticals's investing cash flow?
- Over 3 years (2021 to 2025), Crinetics Pharmaceuticals's investing cash flow has grown at a 45.5% compound annual growth rate (CAGR), from -$56.48M to $173.91M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.